nccn guidelines for first-line treatment of rr-dtc
Published 4 years ago • 109 plays • Length 6:27Download video MP4
Download video MP3
Similar videos
-
2:02
radioiodine-refractory dtc: nccn guidelines
-
19:13
31 first line therapy: the role of biomarkers and nccn guidelines
-
8:08
pancreatic cancer: updated nccn guidelines
-
3:02
defining radioiodine-refractory dtc
-
20:02
management of differentiated thyroid carcinoma in the era of targeted therapy
-
1:09
dr. levy on first-line treatment for nondriver nsclc
-
2:55
initial management of advanced rcc
-
1:01:21
head-to-head comparison of fapi & dotanoc pet/ct imaging for mtc surveillance with dr. bal
-
47:45
241 precision medicine in thyroid cancer: role of molecular diagnostics in optimizing patient care
-
57:45
updates in pancreatic cancer: 2022 - michael pishvaian, md, phd
-
23:16
implementation of multigene testing for 1st line nsclc - a malaysian initiative
-
3:46
changes in nccn guideline: affecting second-line
-
47:08
management of 1st line alk nsclc
-
1:17
expectations for the treatment landscape of differentiated thyroid cancers in the future
-
5:27
differentiated thyroid cancer: initial management
-
2:18
first-, second-, and third-line treatment for nsclc
-
6:53
sequencing in dtc: lenvatinib and sorafenib
-
4:30
molecular testing guideline for patients
-
23:29
transitioning checkpoint blockade from the second to first line in advanced nsclc
-
56:55
the abcs of dtc & variants: understanding key terms, concepts & initial diagnostic & treatment. 154
-
1:06
checkpoint inhibitors advance standard of care for non-small cell lung cancers
-
0:59
dr. martins on managing toxicities associated with lenvatinib in dtc